HRP20120948T1 - Derivati piridina koji su korisni kao aktivatori glukokinaze - Google Patents

Derivati piridina koji su korisni kao aktivatori glukokinaze Download PDF

Info

Publication number
HRP20120948T1
HRP20120948T1 HRP20120948AT HRP20120948T HRP20120948T1 HR P20120948 T1 HRP20120948 T1 HR P20120948T1 HR P20120948A T HRP20120948A T HR P20120948AT HR P20120948 T HRP20120948 T HR P20120948T HR P20120948 T1 HRP20120948 T1 HR P20120948T1
Authority
HR
Croatia
Prior art keywords
image
stereoisomers
proportions
mixtures
pharmaceutically useful
Prior art date
Application number
HRP20120948AT
Other languages
English (en)
Inventor
Lars Thore Burgdorf
Norbert Beier
Johannes Gleitz
Christine Charon
Daniel Cravo
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HRP20120948T1 publication Critical patent/HRP20120948T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (6)

1. Spojevi naznačeni time da su odabrani iz skupine koja sadrži [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] i njihove farmaceutski korisne soli i stereoizomeri, uključujući njihove mješavine u svim omjerima
2. Lijekovi naznačeni time da sadrže barem jedan spoj prema zahtjevu 1 i/ili njihove farmaceutski korisne soli i stereoizomere, uključujući njihove mješavine u svim omjerima, te proizvoljno pomoćne tvari i/ili adjuvante.
3. Uporaba spojeva prema zahtjevu 1, te njihovih farmaceutski korisnih soli i stereoizomera, uključujući njihove mješavine u svim omjerima, naznačena time da je za dobivanje lijeka za liječenje bolesti ili stanja koje proizlazi iz smanjene aktivnosti glukokinaze ili koja se može liječiti pomoću aktivacije glukokinaze.
4. Uporaba prema zahtjevu 3, naznačena time da bolest ili stanje je o inzulinu ovisan dijabetes melitus, dijabetes melitus koji nije ovisan o inzulinu, pretilost, neuropatija i/ili nefropatija.
5. Lijekovi naznačeni time da sadrže barem jedan spoj prema zahtjevu 1, i/ili njihove farmaceutski korisne soli i stereoizomere, uključujući njihove mješavine u svim omjerima, te barem jedan dodatni ljekoviti aktivni spoj.
6. Komplet (kit) naznačen time da sadrži odvojena pakiranja (a) učinkovite količine spoja prema zahtjevu 1 i/ili njegovih farmaceutski korisnih soli i stereoizomera, uključujući njihove mješavine u svim omjerima, i (b) učinkovite količine dodatnog ljekovitog aktivnog spoja.
HRP20120948AT 2007-10-09 2012-11-21 Derivati piridina koji su korisni kao aktivatori glukokinaze HRP20120948T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07019691 2007-10-09
EP08001168 2008-01-23
PCT/EP2008/006649 WO2009046784A1 (en) 2007-10-09 2008-08-13 Pyridine derivatives useful as glucokinase activators

Publications (1)

Publication Number Publication Date
HRP20120948T1 true HRP20120948T1 (hr) 2012-12-31

Family

ID=39870670

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120948AT HRP20120948T1 (hr) 2007-10-09 2012-11-21 Derivati piridina koji su korisni kao aktivatori glukokinaze

Country Status (22)

Country Link
US (1) US8420642B2 (hr)
EP (1) EP2195312B1 (hr)
JP (1) JP5567481B2 (hr)
KR (1) KR20100090250A (hr)
CN (1) CN101821264A (hr)
AR (1) AR068748A1 (hr)
AU (1) AU2008310097B2 (hr)
BR (1) BRPI0818658A2 (hr)
CA (1) CA2701806A1 (hr)
CY (1) CY1113767T1 (hr)
DK (1) DK2195312T3 (hr)
EA (1) EA201000561A1 (hr)
EC (1) ECSP10010158A (hr)
ES (1) ES2399469T3 (hr)
HR (1) HRP20120948T1 (hr)
IL (1) IL204746A0 (hr)
MX (1) MX2010003759A (hr)
NZ (1) NZ585236A (hr)
PL (1) PL2195312T3 (hr)
PT (1) PT2195312E (hr)
SI (1) SI2195312T1 (hr)
WO (1) WO2009046784A1 (hr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2209778T1 (sl) 2007-09-21 2012-12-31 Array Biopharma, Inc. Piridin-2-il-amino-I, 2,4-tiadiazol derivati kot aktivatorji glukokinaze za zdravljenje sladkorne bolezni
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2893699T3 (es) 2010-03-31 2022-02-09 Scripps Research Inst Reprogramación de células
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR112013023054A2 (pt) * 2011-03-09 2019-09-24 Daiichi Sankyo Co Ltd composto, composição farmacêutica, ativador da glicocinase, uso de um composto, métodos para ativação da glicocinase, e para o tratamento e/ou prevenção de uma doença
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
KR102032007B1 (ko) 2012-02-28 2019-10-14 아스텔라스세이야쿠 가부시키가이샤 질소 함유 방향족 헤테로환 화합물
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
AR103264A1 (es) 2014-12-23 2017-04-26 Axikin Pharmaceuticals Inc Derivados de 3,5-aminopirazol como inhibidores de quinasa rc
CN107635981B (zh) 2015-02-17 2020-08-04 中国科学院广州生物医药与健康研究院 用于诱导白色脂肪组织褐变的化合物和方法
AU2016245434B2 (en) * 2015-04-07 2020-10-29 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
CN110568100B (zh) * 2019-09-12 2022-05-31 江西金水宝制药有限公司 一种米格列奈钙r-异构体的检测方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178035B1 (en) * 1984-05-12 1990-01-03 FISONS plc Anti-inflammatory 1,n-diarylpyrazol-3-amines, compositions containing them and processes for their preparation
CA1305478C (en) * 1986-11-06 1992-07-21 Margaret H. Sherlock Naphthyridine and pyridopyrazine compounds and pharmaceutical usage thereof
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
EP0790057B1 (en) 1994-11-29 2002-06-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
WO1996018616A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
WO1996018617A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
JP3892296B2 (ja) 1999-09-10 2007-03-14 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
UY26780A1 (es) 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
DE60108639T2 (de) 2000-07-04 2005-07-07 Neurosearch A/S Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003027101A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
EP1336607A1 (en) * 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
JP2005518391A (ja) * 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
MXPA05008309A (es) 2003-02-10 2005-09-20 Amgen Inc Ligandos de receptor vaniloide y su uso en tratamientos.
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
WO2004110357A2 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20070027321A1 (en) 2003-09-02 2007-02-01 Kamenecka Theodore M Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
JPWO2005090332A1 (ja) * 2004-03-23 2008-01-31 萬有製薬株式会社 置換キナゾリン又はピリドピリミジン誘導体
CA2562242A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycylic thiazoles as potassium ion channel modulators
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
EP1789390B1 (en) 2004-09-02 2011-11-09 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
DE602006020327D1 (de) 2005-01-19 2011-04-07 Bristol Myers Squibb Co 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
EP1863522A4 (en) 2005-03-18 2010-11-10 Univ California CORRECTIVE TO THE PROCESSING OF MUTANT CFTR IMPACT COMPOUNDS AND ITS APPLICATIONS
EP1876178B1 (en) * 2005-04-28 2015-05-27 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
SG159561A1 (en) * 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
CA2614746C (en) * 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1906956A2 (en) 2005-07-21 2008-04-09 Betagenon AB Use of thiazole derivatives and analogues in disorders caused by free fatty acids
CA2615890A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
ATE521608T1 (de) 2005-11-01 2011-09-15 Array Biopharma Inc Glucokinaseaktivatoren
BRPI0618067A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso e processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
ATE539748T1 (de) 2006-01-27 2012-01-15 Array Biopharma Inc Glucokinaseaktivatoren
JP5377284B2 (ja) 2006-03-24 2013-12-25 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼアクチベーターとしての２−アミノピリジンアナログ
WO2008091770A1 (en) 2007-01-24 2008-07-31 Array Biopharma Inc. 2-aminopyridine derivatives as glucokinase activators
JP2010520887A (ja) * 2007-03-09 2010-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリジン
EP2173745A2 (en) * 2007-03-23 2010-04-14 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer

Also Published As

Publication number Publication date
ES2399469T3 (es) 2013-04-01
AU2008310097A1 (en) 2009-04-16
CA2701806A1 (en) 2009-04-16
US8420642B2 (en) 2013-04-16
WO2009046784A1 (en) 2009-04-16
AU2008310097B2 (en) 2013-05-16
JP5567481B2 (ja) 2014-08-06
PL2195312T3 (pl) 2013-04-30
PT2195312E (pt) 2013-02-20
DK2195312T3 (da) 2013-01-02
KR20100090250A (ko) 2010-08-13
EP2195312B1 (en) 2012-11-21
NZ585236A (en) 2012-03-30
CN101821264A (zh) 2010-09-01
JP2010540667A (ja) 2010-12-24
IL204746A0 (en) 2010-11-30
AR068748A1 (es) 2009-12-02
ECSP10010158A (es) 2010-06-29
EA201000561A1 (ru) 2010-10-29
BRPI0818658A2 (pt) 2015-04-14
CY1113767T1 (el) 2016-07-27
EP2195312A1 (en) 2010-06-16
US20100216794A1 (en) 2010-08-26
SI2195312T1 (sl) 2013-01-31
MX2010003759A (es) 2010-04-21

Similar Documents

Publication Publication Date Title
HRP20120948T1 (hr) Derivati piridina koji su korisni kao aktivatori glukokinaze
HRP20150375T1 (hr) Derivati piridazinona
JP2009500443A5 (hr)
NO20072542L (no) Pyrimidinderivat kondensert med ikke-aromatisk ring
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CL2007003614A1 (es) Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
PE20091461A1 (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa
HRP20131120T1 (hr) Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
DE602006019880D1 (de) Verwendung von thienopyridonderivaten als ampk-aktivatoren und pharmazeutische zusammensetzungen, die diese enthalten
WO2010045656A3 (en) Novel sglt2 inhibitor dosage forms
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
CL2008002542A1 (es) Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
NZ594022A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
EP1894567A4 (en) PHARMACEUTICAL COMPANION THERAPIES AND THEIR USE
JP2010222367A5 (hr)
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
JP2008540506A5 (hr)
CR11482A (es) Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
SI1843754T1 (sl) Novi farmacevtski sestavek, ki vsebuje kandesartan cileksetil kot lipofilno kristalinično snov
WO2008092072A3 (en) Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof